| | Item 4 is hereby amended and supplemented to add the following:
On November 15, 2026, Ocho entered into a Cooperation Agreement with the Issuer (the "Cooperation Agreement"). See Item 6.
Subject to the terms of the Cooperation Agreement, the Reporting Persons intend to review their investment in the Issuer on a continuing basis and may, from time to time and at any time, in the open market, in privately negotiated transactions or otherwise, increase or decrease their holdings in the Issuer, in each case in accordance with applicable law and the terms of the Cooperation Agreement. Except as set forth in this Schedule 13D, the Reporting Persons do not presently have any plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. |
| (a) | See responses to Items 7, 8, 9 and 10 on the cover pages of this filing, which are incorporated herein by reference. The percentage ownership is based on 27,688,181 shares outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 13, 2026. Restricted shares of Common Stock awarded in connection with Mr. Upitis joining the Issuer's board of directors (as detailed in Item 5(c) below) have been excluded because they do not vest within 60 days of this amendment. |
| (c) | The Reporting Persons participated in a registered direct offering of Common Stock by the Issuer on September 30, 2026. The Reporting Persons acquired 3,675,000 additional shares in connection with the offering. In connection with Mr. Upitis joining the Issuer's board of directors, Mr. Upitis was granted an initial award of shares of restricted Common Stock having an aggregate value of approximately $200,000 and representing 28,092 underlying whole shares. These shares vest over the three-year period commencing on the date of grant, with 1/3 of the shares vesting on each of the first three anniversaries of the date of grant. Mr. Upitis was also automatically granted a prorated annual award of shares of restricted Common Stock having an aggregate value of approximately $45,418.33 and representing 6,379 underlying whole shares that will vest on the first anniversary of the grant date, or immediately prior to the next annual meeting of shareholders that occurs prior to such first anniversary, but at least 50 weeks after the prior year's annual meeting of shareholders. None of the restricted shares of Common Stock vest within 60 days of this amendment. The Reporting Persons have not effected any other transactions in the Common Stock during the past sixty days. |
| | The information in Items 3, 4, and 5 of this filing is incorporated herein by reference.
Cooperation Agreement
On November 15, 2026 (the "Effective Date"), Ocho and the Issuer entered into the Cooperation Agreement.
Pursuant to the Cooperation Agreement, the Board increased its size from eight (8) to eleven (11) directors and appointed (i) Andris Upitis, the Manager of Ocho and a Reporting Person (the "First New Director"), and (ii) Kevin McConnell and Amy O'Keefe (together with the First New Director, the "New Directors") to fill the three resulting vacancies, in each case with an initial term expiring at the 2027 Annual Meeting (as defined below) and until such director's successor has been duly elected and qualified or such director's earlier death, resignation or removal. Mr. Upitis was appointed to the Governance, Nominating and Sustainability Committee (the "Nominating Committee") and the Compensation and Talent Management Committee (the "Compensation Committee"). Mr. McConnell was appointed to the Nominating Committee and Ms. O'Keefe was appointed to the Audit Committee and the Compensation Committee. The Issuer has agreed to nominate each of the New Directors (or any Replacement Candidate (as defined below)) for election to the Board at the Issuer's 2027 annual meeting of shareholders (the "2027 Annual Meeting") and to recommend, support and solicit proxies for their election in a manner no less rigorous and favorable than the manner in which the Issuer supports its other director nominees.
Immediately prior to the Effective Date, the Issuer received the irrevocable written resignations of LaShonda Anderson-Williams, Sheila Cheston and Katie Kool from the Compensation Committee, effective as of the Effective Date, and from the Board, effective as of December 31, 2026, and of Sandeep Dadlani from the Board, effective as of December 31, 2026, each of which the Board irrevocably accepted.
Without the prior written consent of Ocho, the size of the Board may not exceed (i) eleven (11) directors from the Effective Date until the effectiveness of the director resignations on December 31, 2026, and (ii) nine (9) directors following the effectiveness of such resignations and until the Termination Date (as defined below).
If any New Director ceases to be a director prior to the Termination Date, Ocho has the right to designate a substitute director, subject to such candidate being deemed reasonably acceptable by the Nominating Committee and satisfying certain customary director criteria. In addition, in lieu of the renomination of any New Director, or of one (1) director who joins the Board after the Effective Date other than a New Director (an "Additional Director"), at the 2027 Annual Meeting, Ocho has the right to designate a replacement candidate for nomination at the 2027 Annual Meeting (a "Replacement Candidate"), subject to the same Nominating Committee acceptance and director criteria. If two or more Additional Directors join the Board, the Issuer will have a veto right with respect to the Additional Director to be replaced.
From the Effective Date until the Termination Date (the "Standstill Period"), Ocho has agreed to appear in person or by proxy at each annual or special meeting of shareholders of the Issuer and to vote in accordance with the Board's recommendations with respect to (a) the election, removal or replacement of any director and (b) any other proposal submitted to shareholders; provided, however, that Ocho may vote in accordance with the recommendations of Institutional Shareholder Services Inc. or Glass Lewis & Co. LLC, should they differ from the recommendation of the Board (other than with respect to the election, removal or replacement of the Issuer's directors, the Issuer's "say-on-pay" proposal, the authorization of Issuer shares or the issuance of equity in connection with employee compensation). Ocho may vote in its sole discretion on any proposal with respect to any Extraordinary Transaction (as defined in the Cooperation Agreement), the ratification or approval of any shareholder rights plan, and any amendment to the Issuer's articles of incorporation or bylaws that would reasonably be expected to adversely affect the rights of the Issuer's shareholders.
During the Standstill Period, Ocho has agreed to customary standstill restrictions, and mutual non-disparagement obligations and a no-litigation provision. The standstill restrictions do not prohibit Ocho from, among other things, making statements with respect to a publicly announced Extraordinary Transaction, or trading in broad-based index funds. The Cooperation Agreement also contains customary confidentiality obligations and expense reimbursement provisions.
The voting, Ocho non-disparagement, no-litigation and standstill restrictions will terminate automatically upon the earlier of (A) a material breach by the Issuer of its obligations under the Cooperation Agreement, subject to the opportunity to cure; and (B) the Issuer's entry into a definitive agreement with respect to certain significant transactions as set forth in the Cooperation Agreement.
The Cooperation Agreement will remain in effect until the earlier of (a) December 31, 2027 and (b) the date that is thirty (30) days prior to the first day of the window under the Issuer's bylaws for the submission of shareholder director nominations for the 2028 Annual Meeting (the "Termination Date"). Either party may terminate the Cooperation Agreement earlier if the other party commits a material breach, subject to the opportunity to cure.
The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement, which is attached as Exhibit 99.1 hereto and is incorporated herein by reference. |